Monitor ZEVASKYN treatment volume and QTC activation pace in Q4, as revenue growth depends on batch release consistency and hospital adoption. The PIPE and asset acquisition add dilution risk but provide capital for ABO-801 development.
Drugs in focus
ABEO drug pipeline →ABO-801
● Neutral Named in this press release- Impact
- Phase
- Phase 2 completed / Phase 3-ready
- Time to market
- ABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.
- Next catalyst
- None dated
What to watchWatch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $2.54entry
- T+1 · 7d ago −3.35%α −2.98% · $2.46
- T+5 · 18h ago +2.36%α +4.05% · $2.60
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics reported Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially, with a net loss of -$0.08 per share, beating the consensus EPS estimate of -$0.17. The company also announced a $30M PIPE financing and the acquisition of Phase 3-ready ABO-801 for EoE, which together dilute existing shareholders by approximately 13-15%.
Key Financial Metrics
Key Facts
- Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially from $11.4M in Q2 2026
- Net loss of $(4.8)M or $(0.08) per share, compared to consensus EPS estimate of $(0.17)
- Cash, cash equivalents and short-term investments of $134.9M as of September 30, 2026
- Separately announced $30M PIPE financing at $3.75 per share and acquisition of ABO-801 for $20M in stock
- 15 ZEVASKYN treatments completed since launch, including 6 in Q3; QTC network expanded to 8 sites
- NTAP status for ZEVASKYN effective October 1, 2026
Financial Impact
EPS beat of $0.09 vs consensus; sequential revenue growth of $2.1M; PIPE and acquisition dilute existing shares by ~13-15% based on $224M market cap
Risk Factors
- Dilution from $30M PIPE and $20M stock-based acquisition, totaling ~13-15% of market cap
- ZEVASKYN revenue recognition depends on batch release criteria; one Q3 treatment was not recognized due to identity assay failure
- ABO-801 is pre-revenue and requires FDA approval and commercial buildout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398199 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers